Wednesday, 2 September 2015

Global dry eye syndrome market to grow at a CAGR of 4.75% over the period 2014-2019

Product Synopsis

About dry eye syndrome
Dry eye syndrome usually results in dryness of eyes due to deficient tear production or quick tear evaporation or deviation in tear uniformity. This syndrome is of two types: aqueous tear deficient dry eye and evaporative dry eye. In aqueous tear deficient dry eye, lacrimal glands do not produce enough tears, whereas meibomian gland dysfunction results in evaporative dry eye. Meibomian glands secrete lipids to slow tear evaporation and maintain tear stability. The symptoms include pain, redness, burning, and fatigue in the eye and decreased tolerance to continuous visual activity. Dry eye syndrome cannot be cured, but symptoms can be controlled. Teardrops and anti-inflammatory drugs are used in the treatment.


Technavio's analysts forecast the global dry eye syndrome market to grow at a CAGR of 4.75% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global dry eye syndrome market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of teardrops and anti-inflammatory drugs used in the treatment of dry eye syndrome.

Technavio's report, Global Dry Eye Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation. The report includes a discussion of the key vendors operating in this market.

Key regions
Americas
APAC
EMEA

Key vendors
Alcon
Allergan
Otsuka Holdings
Santen Pharmaceuticals

Other prominent vendors
Acadia Pharmaceuticals 
Aciex
Allostera Pharma
arGentis 
Auven Therapeutics (Celtic)
Bridge Pharma
Can-Fite
Cellzome


Key market driver
Growing prevalence of dry eye syndrome
For a full, detailed list, view our report

Key market challenge
Self-medication by patients
For a full, detailed list, view our report

Key market trend
Growing awareness about the syndrome
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted by at No comments:

Global Duchenne muscular dystrophy drugs market to grow at a CAGR of 152.3% over the period 2014-2019

About Duchenne muscular dystrophy
Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death. The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.


Technavio's analysts forecast the global Duchenne muscular dystrophy drugs market to grow at a CAGR of 152.3% over the period 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the global Duchenne muscular dystrophy drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of Duchenne muscular dystrophy.

Based on mechanism of action of the drugs, the market is segmented as follows: 
• Exon skipping mechanism
• Premature stop codon red through mechanism
• Others

This report includes a discussion of the market in the following three regions: 
• Americas: the US, Canada, Mexico, and Brazil
• EMEA: the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
• APAC: Japan, China, Australia, Singapore, South Korea, and India.


The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio's report, Global Duchenne Muscular Dystrophy Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global Duchenne muscular dystrophy drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
• Americas
• APAC
• EMEA

Key vendors
• BioMarin Pharmaceutical 
• Eli Lilly
• PTC Therapeutics
• Santhera Pharmaceuticals
• Sarepta Therapeutics

Other prominent vendors
• Acceleron Pharma
• Akashi Therapeutics 
• Asklepios BioPharmaceuticals
• Bristol-Myers Squibb
• Capricor Therapeutics
• Catabasis Pharmaceuticals 
• Janssen Pharmaceuticals 
• Lexicon Pharmaceuticals
• Marathon Pharmaceuticals
• Nippon Shinyaku
• Nobelpharma 
• Pfizer 
• Summit Therapeutics 
• Taiho Pharmaceutical

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Market driver
• Significant unmet medical need
• For a full, detailed list, view our report

Market challenge
• High cost 
• For a full, detailed list, view our report

Market trend
• Focus on novel targets
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted by at No comments:

Global Medical Electrodes Market 2014-2018 with a CAGR of 12.20 percent for the period 2013–2018

Product Synopsis

TechNavio forecasts The Global Medical Electrodes Market 2014-2018 with a CAGR of 12.20 percent for the period 2013–2018. Several driving factors and trends will contribute to this growth-all of which will be outlined with detail in this report.

TechNavio’s analysts use a unique methodology to scrutinize individual vendor performance, trends, drivers and challenges, and a number of other factors to provide the most accurate and detailed market research reports possible.


A more specific breakdown of this report’s contents is below.

Overview of market share and landscape for the following key geographies:

APAC
EMEA
Americas
Overview and impact analysis of:

3 Market Drivers
4 Market Challenges
3 Market Trends
Market Shares and SWOT Analysis for these vendors:

3M Corp.
Ambu A/S
CR Bard Inc.
Covidien plc
ConMED Corp.
Cardinal Health Inc.
Five Force Model Impact Analysis of:
Suppliers
Buyers
Substitutes
New entrants
Market competition

Table of Content

1. Executive Summary

2. List of Abbreviations

3. Scope of the Report
3.1 Market Overview
3.2 Product Offerings


4. Market Research Methodology
4.1 Market Research Process
4.2 Research Methodology

5. Introduction

6. Market Landscape
6.1 Market Overview
6.2 Market Size and Forecast
6.3 Five Forces Analysis

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted by at No comments:
Labels: ,

Global implantable medical devices market to grow at a CAGR of 8.54% over the period 2014-2019

Product Synopsis

About implantable medical devices
Implantable medical devices are artificial implants used to replace, augment, or repair damaged tissues or organs. They are used in a wide range of applications including cosmetic, spinal, cardiovascular, ophthalmic, and neuro-stimulator implantation surgeries. These implants are made of different materials such as polymers, metals, ceramics, and biologics.

Technavio's analysts forecast the global implantable medical devices market to grow at a CAGR of 8.54% over the period 2014-2019.


Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the global implantable medical devices market for 2015-2019. To calculate the market size, we consider revenue generated from the sale of the following: breast implants, dental implants, and facial implants.

Technavio's report, Global Implantable Medical Devices Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. In addition, it discusses the major drivers influencing market growth and the challenges faced by vendors and the market as a whole. It also examines key emerging trends and their influence on current and future market scenarios.

Key regions 
Americas
APAC
EMEA

Key vendors
Allergan (a subsidiary of Actavis)
Johnson & Johnson 
Nobel Biocare (a subsidiary of Danaher) 
Straumann 
Stryker

Other prominent vendors
3M Healthcare
AQTIS Medical
Arion Laboratories
Bioha Laboratories
BioHorizons
Biomet 
Camlog Holding (a subsidiary of Henry Schein Canada)
CEREPLAS
Dentsply 
Establishment Labs


GC 
GROUPE SEBBIN
Guangzhou Wanhe Plastic Materials
Hans Biomed
Heraeus Holding 
Ideal Implant
Implantech
Ivoclar Vivadent
Osstem Implant
POLYTECH Health & Aesthetics
Silimed
Spectrum Designs Medical
Sweden & Martina
Ulthera
Zimmer Holdings

Market driver
Rise in aging population 
For a full, detailed list, view our report

Market challenge
High cost of implants 
For a full, detailed list, view our report

Market trend
Importance of medical aesthetics 
For a full, detailed list, view our report

For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted by at No comments:
Labels: ,

China Telemedicine and Online Healthcare Industry, 2015 Key Trends, Size, Growth, Shares And Forecast Research Report

Product Synopsis

Due to the severely imbalanced medical resources,telemedicine and online healthcare have huge development penitential in China. The rapid development of medical informatization and wearable devices have and will continue to boost the bright prospect of telemedicine and online healthcare in China.

By the end of 2014, 50% of provincial level hospitals and 42% of primary hospitals has built up telemedicine centers in China respectively. Viewing from specific businesses, expert consultation is the most developed business, along with medical image consultation, education & training and pathology consultation.


Approximate RMB 16.36 billion been invested on telemedicine in China in 2014, among which, PACS System, Regional Medical Information Platform and HIS System ranked the top 3 segments with investment amount of RMB 3.74, 3.06 and 1.84 billion respectively.

Policies have largely limited the development of online healthcare in China. In August 2014, NHFPC of China released the ‘Advanced on the Telemedicine Services among Medical Institutions’, which stipulated that non-medical institutions cannot develop telemedicine, only health consultation is permitted.


Even so, the market size of online healthcare industry in China still reached RMB 10.88 billion in 2014, where transaction revenue accounts for more than 90% of the market share along with the decreased advertisement revenue in recent 5 years. It’s worth noting that smart devices accounts for 3.1% of the total transaction revenue in China in 2014. Currently the smart devices and services have not fully connected, this segment remains in the incubation period.

The huge demand for telemedicine has already attracted some leading enterprises to invest in Chinese telemedicine market. The largest radiology service company in the US, vRad, signed a strategic cooperation agreement with E-TECHCO in April 2014. Both sides will provide tele radiology services for patients in the greater China region. The largest telemedicine consultation and service institution, WorldCare, has set up the ‘China WorldCare (Beijing) Hospital Management Co., Ltd. Meanwhile, World Care has reached cooperation intentions with many regional goverments such as Nanjing. Mayo Clinic, built up a joint venture with HILLHOUSE Capital in January 2015.


About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact: 

Mr. Nachiket, 
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
State Tower 
90 State Street, Suite 700 
Albany, NY 12207 
United States 
Posted by at No comments:
Labels: , , , ,

Biliary Cirrhosis - Pipeline Review, H2 2015 : Global Industry Growth, Research, Analysis, Shares and Forecast

Product Synopsis

Biliary Cirrhosis - Pipeline Review, H2 2015

Summary

Global Markets Directs, Biliary Cirrhosis - Pipeline Review, H2 2015, provides an overview of the Biliary Cirrhosiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Biliary Cirrhosis and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Biliary Cirrhosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Biliary Cirrhosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Biliary Cirrhosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Biliary Cirrhosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products


Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Biliary Cirrhosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Biliary Cirrhosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted by at No comments:
Labels: , , ,

Trauma - Pipeline Review, H2 2015 : Global Industry Growth, Research, Analysis, Shares and Forecast

Product Synopsis

Trauma - Pipeline Review, H2 2015

Summary

Global Markets Directs, Trauma - Pipeline Review, H2 2015, provides an overview of the Traumas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Trauma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trauma and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Trauma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Trauma and enlists all their major and minor projects


- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Trauma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Trauma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Trauma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Trauma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948

Posted by at No comments:
Subscribe to: Posts (Atom)